Annexon ANNX
NASDAQ ANNX
$4.86 +0.02 (+0.52%)
As of: Sep 4, 2026 · 2:38 PM EDT

Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026)

Annexon (ANNX) posted quarterly Net Income towards Common Stockholders of -$78.1 million for Q1 2026, down 9.25% year-over-year from -$86.0 million in Q1 2025, and down 61.78% quarter-over-quarter from -$48.3 million in Q4 2025.

Analysis

Annexon (ANNX) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

Annexon's Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at -$78.1 million for Q1 2026.

  • In Q1 2026, Net Income towards Common Stockholders fell 9.25% year-over-year to -$78.1 million; the TTM figure through Mar 2026 stood at -$232.3 million (down 25.9% YoY), while the FY2025 annual figure was -$208.5 million, down 50.9% from the prior year.
  • Net Income towards Common Stockholders for Q1 2026 stood at -$78.1 million, down from -$48.3 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was -$29.6 million in Q2 2024, with the low at -$160.9 million in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$51.0 million (2025), against an average of -$59.2 million.
  • The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders sank 367.93% in 2023, then jumped 69.8% in 2024.
  • Annexon's Net Income towards Common Stockholders stood at -$34.4 million in 2022, then tumbled by 367.93% to -$160.9 million in 2023, then surged by 69.8% to -$48.6 million in 2024, then increased by 0.69% to -$48.3 million in 2025, then sank by 61.78% to -$78.1 million in 2026.
  • Business Quant data shows ANNX's Net Income towards Common Stockholders at -$78.1 million in Q1 2026, -$48.3 million in Q4 2025, and -$54.9 million in Q3 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 138.74 Bn 130.89 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.52 Bn 77.52 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 63.51 Bn 58.32 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.04 Bn 52.91 Bn 52.00 Mn -782.00 Mn
5 Revolution Medicines 44.06 Bn 44.06 Bn - -644.37 Mn
6 BeOne Medicines 39.98 Bn 34.88 Bn 1.53 Bn 237.01 Mn
7 Alnylam Pharmaceuticals 35.46 Bn 32.15 Bn 992.69 Mn 164.49 Mn
8 Royalty Pharma 28.41 Bn 27.57 Bn - 81.49 Mn
9 Insmed 27.44 Bn 26.28 Bn 358.27 Mn -13.27 Mn
10 Annexon 978.58 Mn 978.58 Mn - -55.35 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -55.35 Mn
Mar 31, 2026 -46.11 Mn
Dec 31, 2025 -48.26 Mn
Sep 30, 2025 -54.92 Mn
Jun 30, 2025 -51.01 Mn
Mar 31, 2025 -57.51 Mn
Dec 31, 2024 -48.59 Mn
Sep 30, 2024 -34.82 Mn
Jun 30, 2024 -29.61 Mn
Mar 31, 2024 -28.61 Mn
Dec 31, 2023 -29.95 Mn
Sep 30, 2023 -34.73 Mn
Jun 30, 2023 -37.64 Mn
Mar 31, 2023 -41.08 Mn
Dec 31, 2022 -34.38 Mn
Sep 30, 2022 -35.05 Mn
Jun 30, 2022 -37.14 Mn
Mar 31, 2022 -35.37 Mn
Dec 31, 2021 -37.37 Mn
Sep 30, 2021 -35.60 Mn